TrialDiabetologia2026

Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial.

Hongmei Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.